Anticoagulation Considerations in Liver Disease.
| Autor: | Stone AC; Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, Columbus (Dr Stone); and Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus (Drs Gaborcik and Smetana)., Gaborcik JW, Smetana ME |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Critical care nursing quarterly [Crit Care Nurs Q] 2022 Apr-Jun 01; Vol. 45 (2), pp. 156-166. |
| DOI: | 10.1097/CNQ.0000000000000398 |
| Abstrakt: | Coagulopathy of liver disease is a complex pathology that may result in thrombosis and/or bleeding complications. Routine laboratory values are not always reflective of the degree of these risks. Additionally, prophylaxis and treatment of venous thromboembolism in patients with cirrhosis require careful evaluation when selecting and monitoring drug therapy for these indications. Therefore, this article aims to provide insight regarding coagulopathy of liver disease, influence on laboratory values, and anticoagulant therapy considerations for critical care nurses assuming care for patients with cirrhosis. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|